Zhao Liu1, Zhao Song1, Jing Sun2, Fenglei Sun1, Chuanzhi Li1, Jiuzheng Sun1, Liyou Xu1. 1. Department of Hepatobiliary and Pancreatic Surgery, Jinan Central Hospital Affiliated to Shandong University Jinan 250013, Shandong, China. 2. Department of Radiology, Jinan Central Hospital Affiliated to Shandong University Jinan 250013, Shandong, China.
Abstract
AIMS: Our study aimed to investigate the association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) rs231775 polymorphism with hepatocellular carcinoma (HCC) susceptibility. METHODS: Genotypes distribution of the control was tested by Hardy-Weinberg Equilibrium (HWE). CTLA-4 rs231775 polymorphism was analyzed in 80 patients with HCC and 78 healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, and the expression level of CTLA-4 in the serum of all subjects was detected using enzyme linked immunosorbent assay (ELISA) kit. Odd ratio (OR) with 95% confidence interval (CI) were calculated by chi-squared test to determine the correlation of CTLA-4 rs231775 polymorphism and the risk of HCC. RESULTS: The genotypes frequencies of the control group were in accordance with HWE. The frequencies of genotype AA and allele A in CTLA-4 rs231775 polymorphism were significantly higher in cases than the control group (AA vs. GG: OR=2.81, P=0.043; A vs. G: OR=1.63, P=0.022). Meanwhile, the expression level of CTLA-4 was remarkably higher in cases compared with the controls. The association analysis indicated that AA genotype carriers exhibited highest level of CTLA-4 (P<0.01). CONCLUSIONS: The genotype AA and allele A of CTLA-4 rs231775 polymorphism may have negative effects on HCC by modifying the expression and functions of CTLA-4.
AIMS: Our study aimed to investigate the association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) rs231775 polymorphism with hepatocellular carcinoma (HCC) susceptibility. METHODS: Genotypes distribution of the control was tested by Hardy-Weinberg Equilibrium (HWE). CTLA-4rs231775 polymorphism was analyzed in 80 patients with HCC and 78 healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, and the expression level of CTLA-4 in the serum of all subjects was detected using enzyme linked immunosorbent assay (ELISA) kit. Odd ratio (OR) with 95% confidence interval (CI) were calculated by chi-squared test to determine the correlation of CTLA-4rs231775 polymorphism and the risk of HCC. RESULTS: The genotypes frequencies of the control group were in accordance with HWE. The frequencies of genotype AA and allele A in CTLA-4rs231775 polymorphism were significantly higher in cases than the control group (AA vs. GG: OR=2.81, P=0.043; A vs. G: OR=1.63, P=0.022). Meanwhile, the expression level of CTLA-4 was remarkably higher in cases compared with the controls. The association analysis indicated that AA genotype carriers exhibited highest level of CTLA-4 (P<0.01). CONCLUSIONS: The genotype AA and allele A of CTLA-4rs231775 polymorphism may have negative effects on HCC by modifying the expression and functions of CTLA-4.
Authors: E Solerio; G Tappero; L Iannace; G Matullo; M Ayoubi; A Parziale; M Cicilano; G Sansoè; L Framarin; P Vineis; F Rosina Journal: Dig Liver Dis Date: 2005-03 Impact factor: 4.088
Authors: P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak Journal: Science Date: 1995-11-10 Impact factor: 47.728